Home
About
Overview
Sharing Data
ORCID
Help
History (25)
Amico, Andrea
Repeated Ramp Tests on Stable LVAD Patients Reveal Patient-Specific Hemodynamic Fingerprint.
VEGFR-3 neutralization inhibits ovarian lymphangiogenesis, follicle maturation, and murine pregnancy.
Calcification and extracellular matrix dysregulation in human postmortem and surgical aortic valves.
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
See All 25 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. JAMA Oncol. 2020 11 01; 6(11):1694-1695.
View in:
PubMed
subject areas
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Body Weight
Carcinoma, Non-Small-Cell Lung
Delivery of Health Care
Drug Administration Schedule
Drug Dosage Calculations
Drug Packaging
Humans
Lung Neoplasms
Melanoma
Patient Safety
Risk Assessment
Skin Neoplasms
Time Factors
authors with profiles
Mark J. Ratain